EDINBURGH, Scotland and LONDON, Nov. 7, 2025 — Leads & Copy — Resolution Therapeutics Limited, a biopharmaceutical company, announced new clinical and preclinical data supporting Regenerative Macrophage Therapy (RMT) as an anti-inflammatory and anti-fibrotic treatment for cirrhosis. The data will be presented at The Liver Meeting® 2025, hosted by the American Association for the Study of Liver Disease (AASLD) in Washington D.C., from November 7-11, 2025.
Dr. Amir Hefni, Chief Executive Officer of Resolution Therapeutics, expressed confidence in Regenerative Macrophage Therapy’s transformative potential for cirrhosis and the role of engineered macrophages. The EMERALD trial of RTX001, Resolution’s first engineered RMT therapy for end-stage liver disease, is underway, and Dr. Hefni anticipates generating important human data on RTX001 to bring its therapeutic potential to patients.
Dr. Paul Brennan, Clinical Lecturer in Hepatology at the University of Dundee, UK, will present a poster titled “Early modulation of INR and MELD after regenerative macrophage therapy is associated with favorable clinical outcomes at three-year follow-up.” The poster will show that blood tests measuring liver function 90 days post-treatment can predict long-term benefits, with early improvements in clotting factors (INR) and liver disease scores (MELD) correlating with the best outcomes.
Key findings from Dr. Brennan’s presentation include:
- A significant reduction in all-cause mortality and an increase in transplant-free survival at three years among patients treated with Regenerative Macrophages, compared to standard of care (results presented at AASLD 2024).
- Improvement in liver function at 90 days post-dose, measured using biomarkers like INR and MELD, correlated with favorable long-term clinical outcomes.
- The data demonstrate in humans what was previously observed in preclinical studies.
- The initial anti-inflammatory effects of RMT improve liver function and result in later liver remodeling, leading to significant long-term clinical benefit.
Dr. Clifford Brass, Chief Medical Officer of Resolution Therapeutics, noted that this study is the first to show RMT produces early measurable improvements in liver function, which correlate with improved survival, offering hope for patients with limited treatment options. He added that Dr. Brennan’s results are foundational to understanding the mechanism of action driving later liver remodeling in patients with no other treatment options.
Dr. Lara Campana, Scientific Co-Founder and Vice President of Research Operations, Resolution Therapeutics, will present a poster titled “Assessment of regenerative macrophage therapy pharmacology supports anti-inflammatory and anti-fibrotic effects in preclinical models of liver fibrosis,” detailing preclinical data of RTX001 in high-fat diet preclinical models of liver fibrosis.
Key findings from Dr. Campana’s presentation include:
- A single administration of RTX001 in mouse surrogate significantly reduced systemic inflammation in CDAA-HFD models.
- This effect was not observed when mice were treated with non-engineered macrophages.
- Mouse macrophages engineered with IL-10 and MMP9 demonstrated significantly greater anti-inflammatory effect, compared to non-engineered macrophages.
- Distinct molecular signatures of fibrosis progression and regression were identified in the livers of CDAA-HFD mice, providing a new framework to assess anti-fibrotic therapies for end-stage liver disease at a molecular level.
Dr. Campana stated that these preclinical data are the first demonstration of Regenerative Macrophages’ effect on systemic inflammation, achieved by engineering the cells with IL-10 and MMP9. She added that the company is greatly encouraged by these findings, as recent studies have shown systemic inflammation to be a key driver of further decompensation events in end-stage liver disease.
About Resolution Therapeutics:
Resolution Therapeutics is focused on pioneering regenerative macrophage therapy in inflammatory and fibrotic diseases. The Company leverages its proprietary platform to develop macrophages with pro-regenerative properties for superior patient outcomes. Learn more by visiting resolution-tx.com and engage with us on LinkedIn.
Dr Amir Hefni, Chief Executive Officer
Dr Clifford Brass, Chief Medical Officer
Dr Lara Campana, Scientific Co-Founder and Vice President of Research Operations
Source: Resolution Therapeutics Limited
